ロード中...
Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
Classical antagonistic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the PD-1–PDL-1 interaction. Here, we have identified novel antagonistic anti–PD-1 Abs not blocking the PD-1–PDL-1 interaction. The nonblocking Abs recognize epitopes on PD-1 located o...
保存先:
| 出版年: | J Exp Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Rockefeller University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6605749/ https://ncbi.nlm.nih.gov/pubmed/31123083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20182359 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|